<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ901228-0103</DOCNO><DOCID>901228-0103.</DOCID><HL>   Deprenyl Research Ltd. Drug</HL><DATE>12/28/90</DATE><SO>WALL STREET JOURNAL (J), PAGE 10</SO><CO>   DEPLF</CO><IN>DRUG MANUFACTURERS (DRG)</IN><LP>   TORONTO -- Deprenyl Research Ltd. said it is seekingpermission for doctors to prescribe its Eldepryl (R)medication for patients newly diagnosed as suffering fromParkinson's disease.   In Canada, Eldepryl (R) is approved only for treatment ofpatients with advanced-stage Parkinson's disease. Deprenylsaid permission to treat new patients with the drug wasreceived in the United Kingdom in May.</LP><TEXT>   The request for approval to use Eldepryl (R) as initialtherapy in new patients is based on results of clinicalstudies in Canada and the U.S., Deprenyl said.   Eldepryl (R) is being investigated as a possible treatmentfor other neurodegenerative diseases, particularlyAlzheimer's.</TEXT></DOC>